The 28th Annual Prostate Cancer Foundation Scientific Retreat report.
androgen receptor
diagnosis
prognosis
therapy
tumor biology
Journal
The Prostate
ISSN: 1097-0045
Titre abrégé: Prostate
Pays: United States
ID NLM: 8101368
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
21
06
2022
accepted:
24
06
2022
pubmed:
20
7
2022
medline:
1
9
2022
entrez:
19
7
2022
Statut:
ppublish
Résumé
The 28th Annual Prostate Cancer Foundation (PCF) Scientific Retreat was held virtually over 4 days, on October 28-29 and November 4-5, 2021. The Annual PCF Scientific Retreat is a leading global scientific conference that focuses on first-in-field, unpublished, and high-impact basic, translational, and clinical prostate cancer research, as well as research from other fields with high probability for impacting prostate cancer research and patient care. Primary areas of research discussed at the 2021 PCF Retreat included: (i) prostate cancer disparities; (ii) prostate cancer survivorship; (iii) next-generation precision medicine; (iv) PSMA theranostics; (v) prostate cancer lineage plasticity; (vi) tumor metabolism as a cancer driver and treatment target; (vii) prostate cancer genetics and polygenic risk scores; (viii) glucocorticoid receptor biology in castration-resistant prostate cancer (CRPC); (ix) therapeutic degraders; (x) new approaches for immunotherapy in prostate cancer; (xi) novel technologies to overcome the suppressive tumor microenvironment; and (xii) real-world evidence and synthetic/virtual control arms. This article provides a summary of the presentations from the 2021 PCF Scientific Retreat. We hope that sharing this knowledge will help to improve the understanding of the current state of research and direct new advances in prostate cancer research and care.
Sections du résumé
BACKGROUND
The 28th Annual Prostate Cancer Foundation (PCF) Scientific Retreat was held virtually over 4 days, on October 28-29 and November 4-5, 2021.
METHODS
The Annual PCF Scientific Retreat is a leading global scientific conference that focuses on first-in-field, unpublished, and high-impact basic, translational, and clinical prostate cancer research, as well as research from other fields with high probability for impacting prostate cancer research and patient care.
RESULTS
Primary areas of research discussed at the 2021 PCF Retreat included: (i) prostate cancer disparities; (ii) prostate cancer survivorship; (iii) next-generation precision medicine; (iv) PSMA theranostics; (v) prostate cancer lineage plasticity; (vi) tumor metabolism as a cancer driver and treatment target; (vii) prostate cancer genetics and polygenic risk scores; (viii) glucocorticoid receptor biology in castration-resistant prostate cancer (CRPC); (ix) therapeutic degraders; (x) new approaches for immunotherapy in prostate cancer; (xi) novel technologies to overcome the suppressive tumor microenvironment; and (xii) real-world evidence and synthetic/virtual control arms.
CONCLUSIONS
This article provides a summary of the presentations from the 2021 PCF Scientific Retreat. We hope that sharing this knowledge will help to improve the understanding of the current state of research and direct new advances in prostate cancer research and care.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1346-1377Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Yamoah K, Lee KM, Awasthi S, et al. Racial and ethnic disparities in prostate cancer outcomes in the veterans affairs health care system. JAMA Netw Open. 2022;5(1):e2144027.
Rebbeck TR, Mahal B, Maxwell KN, Garraway IP, Yamoah K. The distinct impacts of race and genetic ancestry on health. Nat Med. 2022;28(5):890-893.
Mahal BA, Gerke T, Awasthi S, et al. Prostate cancer racial disparities: a systematic review by the prostate cancer foundation panel. Eur Urol Oncol. 2022;5(1):18-29.
Koga Y, Song H, Chalmers ZR, et al. Genomic profiling of prostate cancers from men with African and European Ancestry. Clin Cancer Res. 2020;26(17):4651-4660.
Rottas M, Thadeio P, Simons R, et al. Demographic diversity of participants in Pfizer sponsored clinical trials in the United States. Contemp Clin Trials. 2021;106:106421.
Narayan V, Harrison M, Cheng H, et al. Improving research for prostate cancer survivorship: a statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. Urol Oncol. 2019;38(3):83-93.
Boyajian Richard N, et al. A virtual prostate cancer clinic for prostate-specific antigen monitoring: improving well visits and freeing up time for acute care. NEJM Catalyst, 2(6). doi:10.1056/CAT.21.0025
Morgans AK, Billes SK, Vetter A, et al. Feasibility of a novel wrist-worn thermal device for management of vasomotor symptoms in patients with prostate cancer. J Clin Oncol. 2022;40(suppl 16):5067.
Sun L, Parikh RB, Hubbard RA, et al. Assessment and management of cardiovascular risk factors among US veterans with prostate cancer. JAMA Netw Open. 2021;4(2):e210070.
Shore ND, Saad F, Cookson MS, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med. 2020;382(23):2187-2196.
Lopes RD, Higano CS, Slovin SF, et al. Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial. Circulation. 2021;144(16):1295-1307.
Sigurdardottir LG, Valdimarsdottir UA, Fall K, et al. Circadian disruption, sleep loss, and prostate cancer risk: a systematic review of epidemiologic studies. Cancer Epidemiol Biomarkers Prev. 2012;21(7):1002-1011.
Robbins R, Jean-Louis G, Chanko N, Combs P, Byrne N, Loeb S. Using data from an online health community to examine the impact of prostate cancer on sleep. BJU Int. 2020;125(5):634-635.
Robbins R, Cole R, Ejikeme C, et al. Systematic review of sleep and sleep disorders among prostate cancer patients and caregivers: a call to action for using validated sleep assessments during prostate cancer care. Sleep Med. 2022;94:38-53.
Dawson JK, Dorff TB, Todd Schroeder E, Lane CJ, Gross ME, Dieli-Conwright CM. Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial. BMC Cancer. 2018;18(1):368.
Dawson JK, Dorff TB, Tuzon C, et al. Effect of periodized resistance training on skeletal muscle during androgen deprivation therapy for prostate cancer: a pilot randomized trial. Integr Cancer Ther. 2021;20:15347354211035442.
Conti DV, Darst BF, Moss LC, et al. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet. 2021;53(1):65-75.
Plym A, Penney KL, Kalia S, et al. Evaluation of a multiethnic polygenic risk score model for prostate cancer. J Natl Cancer Inst. 2022;114(5):771-774.
Dadaev T, Saunders EJ, Newcombe PJ, et al. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nat Commun. 2018;9(1):2256.
Huynh-Le MP, Fan CC, Karunamuni R, et al. Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. Nat Commun. 2021;12(1):1236.
Huynh-Le MP, Fan CC, Karunamuni R, et al. A genetic risk score to personalize prostate cancer screening, applied to population data. Cancer Epidemiol Biomarkers Prev. 2020;29(9):1731-1738.
Karunamuni RA, Huynh-Le MP, Fan CC, et al. African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer. Int J Cancer. 2021;148(1):99-105.
Karunamuni RA, Huynh-Le M-P, Fan CC. Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24. Prostate Cancer Prostatic Dis. 2022;25(2):229-237.
Seibert TM, Fan CC, Wang Y, et al. Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. BMJ. 2018;360:j5757.
Plym A, Zhang Y, Stopsack KH, et al. A healthy lifestyle in men at increased genetic risk for prostate cancer. Eur Urol. 2022. doi:10.1016/j.eururo.2022.05.008
Kenfield SA, Batista JL, Jahn JL, et al. Development and application of a lifestyle score for prevention of lethal prostate cancer. JNCI: J Natl Cancer Inst. 2015;108(3):djv329.
Quigley DA, Dang HX, Zhao SG, et al. Genomic hallmarks and structural variation in metastatic prostate. Cancer Cell. 2018;174(3):758-769.e9.
Zhao SG, Chen WS, Li H, et al. The DNA methylation landscape of advanced prostate cancer. Nat Genet. 2020;52(8):778-789.
Chen WS, Aggarwal R, Zhang L, et al. Genomic drivers of poor prognosis and enzalutamide resistance in metastatic castration-resistant prostate cancer. Eur Urol. 2019;76(5):562-571.
Aggarwal R, Rydzewski NR, Zhang L, et al. Prognosis associated with luminal and basal subtypes of metastatic prostate cancer. JAMA Oncol. 2021;7(11):1644-1652.
Alumkal JJ, Sun D, Lu E, et al. Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. Proc Natl Acad Sci USA. 2020;117(22):12315-12323.
Aggarwal R, Huang J, Alumkal JJ, et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J Clin Oncol. 2018;36(24):2492-2503.
Wyatt AW, Annala M, Aggarwal R, et al. Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer. J Natl Cancer Inst. 2017;109(12). doi:10.1093/jnci/djx118
Chen WS, Haynes WA, Waitz R, et al. Autoantibody landscape in patients with advanced prostate cancer. Clin Cancer Res. 2020;26(23):6204-6214.
Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378(15):1408-1418.
Zhao SG, Chen WS, Das R, et al. Clinical and genomic implications of luminal and basal subtypes across carcinomas. Clin Cancer Res. 2019;25(8):2450-2457.
Frankell AM, Jammula S, Li X, et al. The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic. Nat Genet. 2019;51(3):506-516.
Noorani A, Li X, Goddard M, et al. Genomic evidence supports a clonal diaspora model for metastases of esophageal adenocarcinoma. Nat Genet. 2020;52(1):74-83.
Secrier M, Li X, de Silva N, et al. Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat Genet. 2016;48(10):1131-1141.
He MX, Cuoco MS, Crowdis J, et al. Transcriptional mediators of treatment resistance in lethal prostate cancer. Nat Med. 2021;27(3):426-433.
Armstrong AJ, Luo J, Nanus DM, et al. Prospective multicenter study of circulating tumor cell AR-V7 and taxane versus hormonal treatment outcomes in metastatic castration-resistant prostate cancer. JCO Precis Oncol. 2020;4:PO.20.00200.
Brown LC, Halabi S, Schonhoft JD, et al. Circulating tumor cell chromosomal instability and neuroendocrine phenotype by immunomorphology and poor outcomes in men with mCRPC treated with abiraterone or enzalutamide. Clin Cancer Res. 2021;27(14):4077-4088.
Gupta S, Halabi S, Kemeny G, et al. Circulating tumor cell genomic evolution and hormone therapy outcomes in men with metastatic castration-resistant prostate cancer. Mol Cancer Res. 2021;19(6):1040-1050.
Zhang Z, Zhou C, Li X, et al. Loss of CHD1 promotes heterogeneous mechanisms of resistance to AR-targeted therapy via chromatin dysregulation. Cancer Cell. 2020;37(4):584-598e11.
Beltran H, Prandi D, Mosquera JM, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016;22(3):298-305. doi:10.1038/nm.4045
Bishop JL, Thaper D, Vahid S, et al. The master neural transcription factor BRN2 is an androgen receptor-suppressed driver of neuroendocrine differentiation in prostate. Cancer. Cancer Discov. 2017;7(1):54-71.
Davies A, Nouruzi S, Ganguli D, et al. An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer. Nat Cell Biol. 2021;23(9):1023-1034.
Nouruzi S, Ganguli D, Tabrizian N, et al. ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer. Nat Commun. 2022;13(1):2282.
Mandigo AC, Yuan W, Xu K, et al. RB/E2F1 as a master regulator of cancer cell metabolism in advanced disease. Cancer Discov. 2021;11(9):2334-2353.
Li J, Berk M, Alyamani M, et al. Hexose-6-phosphate dehydrogenase blockade reverses prostate cancer drug resistance in xenograft models by glucocorticoid inactivation. Sci Transl Med. 2021;13(595), eabe8226.
Valle S, Sharifi N. Targeting glucocorticoid metabolism in prostate cancer. Endocrinology. 2021;162(9).
Isikbay M, Otto K, Kregel S, et al. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Horm Cancer. 2014;5(2):72-89.
Kach J, Long TM, Selman P, et al. Selective glucocorticoid receptor modulators (SGRMs) delay castrate-resistant prostate cancer growth. Mol Cancer Ther. 2017;16(8):1680-1692.
Hickey TE, Selth LA, Chia KM, et al. The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer. Nat Med. 2021;27(2):310-320.
Labbé DP, Zadra G, Yang M, et al. High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program. Nat Commun. 2019;10(1):4358.
Priolo C, Pyne S, Rose J, et al. AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer. Cancer Res. 2014;74(24):7198-7204.
Zadra G, Ribeiro CF, Chetta P, et al. Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer. Proc Natl Acad Sci USA. 2019;116(2):631-640.
Miyahira AK, Soule HR. The history of prostate-specific membrane antigen as a theranostic target in prostate cancer: the cornerstone role of the Prostate Cancer Foundation. J Nucl Med. 2022;63(3):331-338.
Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208-1216.
Hofman MS, Emmett L, Sandhu S, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797-804.
Buteau JP, Martin AJ, Emmett L, et al. PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603). J Clin Oncol. 2022;40(suppl 6):10.
Hofman MS, Emmett L, Sandhu S, et al. TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-overall survival after median follow-up of 3 years (ANZUP 1603). J Clin Oncol. 2022;40(suppl 16):5000.
Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for netastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091-1103.
Kiess AP, Minn I, Vaidyanathan G, et al. (2S)-2-(3-(1-Carboxy-5-(4-211At-astatobenzamido)pentyl)ureido)-pentanedioic acid for PSMA-targeted alpha-particle radiopharmaceutical therapy. J Nucl Med. 2016;57(10):1569-1575.
Shen CJ, Minn I, Hobbs RF, et al. Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen in a micrometastatic model of prostate cancer. Theranostics. 2020;10(7):2888-2896.
Armstrong AJ, Edenbrandt L, Bondesson E, et al. Phase 3 prognostic analysis of the automated bone scan index (aBSI) in men with bone-metastatic castration-resistant prostate cancer (CRPC). J Clin Oncol. 2017;35(suppl 15):5006.
Ali A, Hoyle AP, Parker CC, et al. The automated bone scan index as a predictor of response to prostate radiotherapy in men with newly diagnosed metastatic prostate cancer: an exploratory analysis of STAMPEDE's “M1|RT comparison”. Eur Urol Oncol. 2020;3(4):412-419.
Johnsson K, Brynolfsson J, Sahlstedt H, et al. Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [(18)F]DCFPyL (PSMA) imaging for standardized reporting. Eur J Nucl Med Mol Imaging. 2022;49(3):1041-1051.
Nickols N, Anand A, Johnsson K, et al. aPROMISE: a novel automated PROMISE platform to standardize evaluation of tumor burden in (18)F-DCFPyL images of veterans with prostate cancer. J Nucl Med. 2022;63(2):233-239.
Xiao L, Parolia A, Qiao Y, et al. Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer. Nature. 2022;601(7893):434-439.
Guan X, Polesso F, Wang C, et al. Androgen receptor activity in T cells limits checkpoint blockade efficacy. Nature. 2022;606:791-796.
Wu YM, Cieślik M, Lonigro RJ, et al. Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate. Cancer Cell. 2018;173(7):1770-1782.e14.
Shenderov E, Mallesara GHG, Wysocki PJ, et al. 620P MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: preliminary results of phase I cohort expansion. Ann Oncol. 2021;32:S657-S659.
Subudhi SK, Siddiqui BA, Maly JJ, et al. Safety and efficacy of AMG 160, a half-life extended BiTE immune therapy targeting prostate-specific membrane antigen (PSMA), and other therapies for metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2021;39(suppl 15):TPS5088.
Bendell JC, Fong L, Stein MN, et al. First-in-human phase I study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager in patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2020;38(suppl 15):5552.
Harpoon Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update. 2022. Accessed June 26, 2022. https://www.globenewswire.com/news-release/2022/03/10/2401382/0/en/Harpoon-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-Results-and-Provides-Corporate-Update.html
Kelly WK, Danila DC, Edenfield WJ, et al. Phase I study of AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2020;38(suppl 15):TPS5589.
Madrigal JL, Schoepp NG, Xu L, et al. Characterizing cell interactions at scale with made-to-order droplet ensembles (MODEs). Proc Natl Acad Sci USA. 2022;119(5):e2110867119.
Alba PR, Gao A, Lee KM, et al. Ascertainment of veterans with metastatic prostate cancer in electronic health records: demonstrating the case for natural language processing. JCO Clin Cancer Inform. 2021;5:1005-1014.
Leuva H, Sigel K, Zhou M, et al. A novel approach to assess real-world efficacy of cancer therapy in metastatic prostate cancer. Analysis of national data on veterans treated with abiraterone and enzalutamide. Semin Oncol. 2019;46(4-5):351-361.
Maitland ML, Wilkerson J, Karovic S, et al. Enhanced detection of treatment effects on metastatic colorectal cancer with volumetric CT measurements for tumor burden growth rate evaluation. Clin Cancer Res. 2020;26(24):6464-6474.
Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061-1068.